Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice

Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4

(2011) Daniela Bumbaca et al.   mAbs

Finding the Right Dose for Cancer Therapeutics--Can We Do Better?

(2010) E. H. Rubin et al.   CLINICAL CANCER RESEARCH

Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse

(2010) R. K. Jain et al.   CLINICAL CANCER RESEARCH

Development and Evaluation of a Novel Method for Preclinical Measurement of Tissue Vascular Volume

(2010) C. Andrew Boswell et al.   MOLECULAR PHARMACEUTICS

Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease

(2009) Mohammad Tabrizi et al.   AAPS Journal

Neuropilins in Tumor Biology

(2009) A. Bagri et al.   CLINICAL CANCER RESEARCH

Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody

(2008) Wim K. Bleeker et al.   BRITISH JOURNAL OF HAEMATOLOGY

Dose Selection in Phase I Studies: Why We Should Always Go for the Most Effective

(2008) Ian E. Haines   JOURNAL OF CLINICAL ONCOLOGY